Thermo Fisher (NYSE: TMO) CEO trades 10K shares under 10b5-1 plan

Rhea-AI Filing Summary

Thermo Fisher Scientific Inc. Chairman & CEO Marc N. Casper reported option exercises and related share sales in company stock. On March 3 and 4, 2026, he exercised stock options for a total of 10,000 shares of Common Stock at a reported exercise price of $309.63 per share in multiple transactions coded as derivative exercises.

Over the same two days, Casper sold 10,000 shares of Common Stock in a series of open-market transactions, with prices reported around $495.29–$517.05 per share as weighted-average prices across multiple trades. The transactions were effected under a Rule 10b5-1 trading plan adopted on November 11, 2025. Following these transactions, he directly held 123,925.358 shares of Common Stock and 44,550 stock options. Additional shares are held indirectly through the Alison Casper 2020 Irrevocable Trust, the MNC 2020 Irrevocable Trust, and Floral Park Associates, Inc., for which he disclaims beneficial ownership except for any pecuniary interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CASPER MARC N

(Last) (First) (Middle)

168 THIRD AVENUE

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
THERMO FISHER SCIENTIFIC INC. [ TMO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chairman & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		M		5,000	A	$309.63	128,925.358	D
Common Stock	03/03/2026		S(1)		360	D	$495.29(2)	128,565.358	D
Common Stock	03/03/2026		S(1)		480	D	$496.84(3)	128,085.358	D
Common Stock	03/03/2026		S(1)		680	D	$498.14(4)	127,405.358	D
Common Stock	03/03/2026		S(1)		240	D	$499.75(5)	127,165.358	D
Common Stock	03/03/2026		S(1)		382	D	$500.55(6)	126,783.358	D
Common Stock	03/03/2026		S(1)		360	D	$501.95(7)	126,423.358	D
Common Stock	03/03/2026		S(1)		120	D	$502.59(8)	126,303.358	D
Common Stock	03/03/2026		S(1)		120	D	$504.06(9)	126,183.358	D
Common Stock	03/03/2026		S(1)		448	D	$506.74(10)	125,735.358	D
Common Stock	03/03/2026		S(1)		931	D	$507.9(11)	124,804.358	D
Common Stock	03/03/2026		S(1)		759	D	$508.95(12)	124,045.358	D
Common Stock	03/03/2026		S(1)		120	D	$509.62(13)	123,925.358	D
Common Stock	03/04/2026		M		5,000	A	$309.63	128,925.358	D
Common Stock	03/04/2026		S(1)		447	D	$509.89(14)	128,478.358	D
Common Stock	03/04/2026		S(1)		678	D	$510.71(15)	127,800.358	D
Common Stock	03/04/2026		S(1)		1,370	D	$511.8(16)	126,430.358	D
Common Stock	03/04/2026		S(1)		1,241	D	$512.92(17)	125,189.358	D
Common Stock	03/04/2026		S(1)		815	D	$513.63(18)	124,374.358	D
Common Stock	03/04/2026		S(1)		212	D	$514.86(19)	124,162.358	D
Common Stock	03/04/2026		S(1)		119	D	$515.77(20)	124,043.358	D
Common Stock	03/04/2026		S(1)		118	D	$516.75(21)	123,925.358	D
Common Stock								11,300	I	By Alison Casper 2020 Irrevocable Trust(22)
Common Stock								14,608	I	By Floral Park Associates, Inc.
Common Stock								5,000	I	By MNC 2020 Irrevocable Trust(23)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$309.63	03/03/2026		M			5,000	(24)	02/25/2027	Common Stock	5,000	$0	49,550	D
Stock Option (Right to Buy)	$309.63	03/04/2026		M			5,000	(24)	02/25/2027	Common Stock	5,000	$0	44,550	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 11, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $495.08 to $495.46, inclusive. The reporting person undertakes to provide to Thermo Fisher Scientific Inc. ("TMO"), any security holder of TMO or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), (16), (17), (18), (19), (20), and (21) to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $496.43 to $497.37, inclusive.

4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $497.80 to $498.70, inclusive.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $499.36 to $500.14, inclusive.

6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $500.47 to $501.44, inclusive.

7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $501.56 to $502.36, inclusive.

8. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $502.59 to $502.60, inclusive.

9. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $504.06 to $504.07, inclusive.

10. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $506.40 to $507.38, inclusive.

11. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $507.41 to $508.31, inclusive.

12. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $508.57 to $509.28, inclusive.

13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $509.62 to $509.63, inclusive.

14. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $509.283 to $510.22, inclusive.

15. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $510.32 to $511.277, inclusive.

16. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $511.323 to $512.303, inclusive.

17. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $512.34 to $513.33, inclusive.

18. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $513.341 to $514.328, inclusive.

19. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $514.383 to $515.373, inclusive.

20. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $515.378 to $516.065, inclusive.

21. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $516.57 to $517.046, inclusive.

22. The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.

23. The reporting person disclaims beneficial ownership of the securities reported herein as indirectly beneficially owned, except to the extent of any pecuniary interest therein.

24. The option vested in four equal installments on February 25, 2021, 2022, 2023, and 2024.

	/s/ Melodie T. Morin, Attorney-in-Fact for Marc N. Casper	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Thermo Fisher (TMO) CEO Marc N. Casper report?

Marc N. Casper reported exercising stock options and selling shares of Thermo Fisher common stock. Over March 3–4, 2026, he exercised options for 10,000 shares and sold 10,000 shares in multiple open-market transactions, according to the Form 4 filing.

How many Thermo Fisher (TMO) shares did the CEO sell in this Form 4?

The Form 4 shows Marc N. Casper sold 10,000 shares of Thermo Fisher common stock. These were executed as multiple open-market transactions at weighted-average prices, with individual reported prices generally in the high $400s to low $500s per share.

Did Thermo Fisher (TMO) CEO transactions involve option exercises?

Yes. Marc N. Casper exercised stock options covering 10,000 shares of Thermo Fisher common stock. The Form 4 reports these exercises at an exercise price of $309.63 per share, converting derivative securities into directly held common stock before related open-market sales.

Were Thermo Fisher (TMO) CEO share sales under a Rule 10b5-1 plan?

Yes. The filing states all reported transactions were effected under a Rule 10b5-1 trading plan. This plan was adopted by Marc N. Casper on November 11, 2025, and governs the timing and amount of the reported sales and option exercises.

What is Marc N. Casper’s Thermo Fisher (TMO) direct share ownership after these trades?

After the reported transactions, Marc N. Casper directly held 123,925.358 shares of Thermo Fisher common stock. He also directly held 44,550 stock options. These figures represent his direct holdings as reported following the March 3–4, 2026 transactions.

Does the Thermo Fisher (TMO) CEO have indirect holdings through trusts or entities?

Yes. The Form 4 lists indirect ownership through the Alison Casper 2020 Irrevocable Trust, the MNC 2020 Irrevocable Trust, and Floral Park Associates, Inc. The reporting person disclaims beneficial ownership of these indirect holdings except to the extent of any pecuniary interest.